A composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026)
Titel:
A composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026)
Auteur:
Hennessy, Maeve A. Cimino-Mathews, Ashley Carter, Jodi M. Kachergus, Jennifer M. Ma, Yaohua Leal, Jeffrey P. Solnes, Lilja B. Abramson, Vandana G. Carey, Lisa A. Rimawi, Mothaffar Specht, Jennifer Storniolo, Anna Maria Vaklavas, Christos Krop, Ian Winer, Eric Denbow, Rita Valero, Vincente Wolff, Antonio C. Wahl, Richard L. Huang, Chiung-Yu Stearns, Vered Thompson, E. Aubrey Connolly, Roisin M.